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Abstract  
Neuronal homeostasis is critically dependent on healthy mitochondria. Mutations in 
mitochondrial DNA (mtDNA), in nuclear-encoded mitochondrial components, and age-
dependent mitochondrial damage, have all been connected with neurological disorders. These 
include not only typical mitochondrial syndromes with neurological features such as 
encephalomyopathy, myoclonic epilepsy, neuropathy and ataxia; but also secondary 
mitochondrial involvement in neurodegenerative disorders such as Alzheimer’s, Parkinson’s 
and Huntington’s disease. Unravelling the molecular aetiology of mitochondrial dysfunction 
opens new therapeutic prospects for diseases thus far lacking effective treatments. In this 
review we address recent advances on preventive strategies, such as pronuclear, spindle-
chromosome complex, or polar body genome transfer to replace mtDNA and avoid disease 
transmission to newborns; we also address experimental mitochondrial therapeutics aiming to 
benefit symptomatic patients and prevent disease manifestation in those at risk. Specifically, 
we focus on: (1) gene therapy to reduce mutant mtDNA, such as anti-replicative therapies and 
mitochondria-targeted nucleases allowing favourable heteroplasmic shifts; (2) allotopic 
expression of recoded wild-type mitochondrial genes, including targeted tRNAs and 
xenotopic expression of cognate genes to compensate for pathogenic mutations; (3) 
mitochondria targeted-peptides and lipophilic cations for in vivo delivery of antioxidants or 
other putative therapeutics; and (4) modulation of mitochondrial dynamics at the level of 
biogenesis, fission, fusion, movement and mitophagy. Further advances in therapeutic 
development are hindered by scarce in vivo models for mitochondrial disease, with the bulk of 
available data coming from cellular models. Nevertheless, wherever available, we also 
address data from in vivo experiments and clinical trials, focusing on neurological disease 
models. 
 
1. INTRODUCTION 
 
Neuronal physiology is intricately linked with mitochondrial bioenergetics and dynamics. It 
comes therefore at no surprise that mitochondrial failure eventually leads to neuronal demise. 
Mitochondrial dysfunction may in fact affect multiple organs or tissues, but the energetic 
needs and the non-dividing nature of neurons place the nervous system at particularly high 
risk. Neuronal ion balance continuously demands ATP from an active mitochondrial 
respiratory chain [1], which integrates five multi-subunit complexes embedded in the inner 
mitochondrial membrane (IMM). With the exception of complex II, fully encoded by nuclear 
DNA (nDNA), all other respiratory complexes have a dual genetic origin, with some subunits 
encoded by nDNA and others by mitochondrial DNA (mtDNA). Respiratory complexes 
require nDNA-encoded factors for proper assembly and addition of prosthetic groups. In fact, 
the nucleus encodes all proteins involved in mtDNA replication, transcription, translation and 
repair, as well as mt-tRNA synthetases, mitochondrial ribosomal proteins, and proteins 
involved in maintaining the mitochondrial deoxynucleoside triphosphate pool [2]. Multiple 
Mendelian-inherited nDNA mutations may thus cause respiratory chain dysfunction. 
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Primary mitochondrial dysfunction also arises from mutations in mtDNA, which encodes 
13 respiratory chain subunits plus 2 rRNAS and 22 tRNAs required for intra-mitochondrial 
protein synthesis. Specific features of mitochondrial genetics include the (practically) 
exclusive maternal inheritance of multiple mtDNA copies, which can be identical 
(homoplasmy) or different within the same cell (heteroplasmy). Also, random mitotic 
segregation of mtDNA, variable heteroplasmy, potential for clonal expansion, and diverse 
mutational thresholds, condition the differential expression of biochemical defects across cells 
and tissues [3]. Such idiosyncratic features contribute for a wide variability of mitochondrial 
disease manifestation and for the complex clinical maze of mitochondrial neurology [4]. 
Neurological symptoms accompany several diseases resulting from mtDNA mutations, 
namely, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes 
(MELAS); myoclonic epilepsy and ragged red fibres (MERRF); neuropathy, ataxia, and 
retinitis pigmentosa (NARP); Leber’s hereditary optic neuropathy (LHON); and maternally 
inherited Leigh syndrome, among others [5]. It is instructive that complex I deficiency in 
Leigh syndrome may stem not only from mutations in mtDNA but also in the nDNA-encoded 
subunits and assembly factors [2]. In fact, even when mtDNA is free from pathogenic 
mutations and all nuclear-encoded respiratory complex subunits are correctly expressed; 
multiple ‘indirect hits’ can still cause mitochondrial-associated neurological disease. 
Mutations in respiratory chain ancillary proteins are key examples of such indirect hits. Also, 
mutations in the mt-RNA translation machinery, in enzymes governing the IMM lipid milieu, 
and in coordinators of the mitochondrial fission-fusion equilibrium are increasingly identified 
as causes for neurological disorders [4]. The latter are typically illustrated by mutations in the 
pro-fusion proteins OPA1 and Mfn2, respectively associated with dominant optic atrophy and 
Charcot-Marie-Tooth type 2A neuropathy. Loss of function mutations in PINK1 and Parkin, 
causing hereditary Parkinson’s disease (PD), provide another key link between abnormal 
mitochondrial dynamics, in this case mitophagy, and neurodegeneration. Even when 
mitochondrial damage is a secondary pathological event, it still plays a prominent role in key 
neurodegenerative disorders such as Alzheimer’s disease (AD), Huntington’s disease (HD) 
and spinocerebellar ataxias, amyotrophic lateral sclerosis, and several others [6, 7]. 
Interestingly, differences in mitochondrial physiology across brain regions may contribute, 
together with other cellular and environmental factors, for differential vulnerability patterns to 
neurological disease [8, 9]. 
Experimental models of mitochondrial disease are primarily cell-based. Cytoplasmic 
hybrid cells (cybrids; generated by depleting host cells from endogenous mtDNA and 
repopulating with mtDNA from patient cells), are widely used to address the relative 
contribution of nuclear vs. mitochondrial backgrounds for a given disease [10]. The yeast 
Saccharomyces cerevisae is also widely used due to the feasibility of mitochondrial genetic 
transformation in this organism [11]. Still, neither yeast nor cybrids model neuron-specific 
traits, much less model the complex features of a whole organism. To address these issues, 
mouse embryonic stem cells cybrids containing mtDNA mutation have been differentiated 
into neurons [12], and multiple techniques are available for the study of mitochondrial 
function in live neurons [13]. Mitochondrial disease caused by some nDNA mutations has 
already been modelled in mice by nuclear transgenesis, but mtDNA mutations are more 
challenging to model in animals [14]. Still, progresses are being made in the development of 
mouse models of mtDNA defects [15], and models of mitochondrial disease are also being 
developed in zebrafish, drosophila and Caenorhabditis elegans [16-19]. 
A systematic review of clinical data on mitochondrial therapeutics revealed that although 
statistically significant clinical improvements are reported in low-quality studies, they were 
not confirmed by subsequent high-quality studies. Currently prescribed drugs, consisting 
mostly of vitamin supplements, metabolic precursors and antioxidants lack convincing 
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evidence for efficacy other than that expected for placebo. Further, ‘symptomatic 
improvements’ due to normal growth and development (in the case of affected children), and 
regression to mean symptoms (in diseases where symptoms randomly fluctuate), are not 
always adequately controlled for in available trials [20]. There is therefore a great need for 
persistent improvement in clinical trial design, identification of reliable biomarkers, and 
further basic research on disease mechanisms and experimental therapeutics. In this review, 
we address recent advances on preventive strategies associated with assisted reproduction 
techniques, such as pronuclear, spindle-chromosome complex, or polar body genome transfer. 
We also address experimental mitochondrial therapeutics aiming to benefit symptomatic 
patients and prevent disease manifestation in those at risk. We focus on advances in different 
modalities of gene therapy, mitochondria-targeted drugs, and modulators of mitochondrial 
dynamics. The bulk of current data comes from cell-based experiments, nevertheless, 
wherever available, we address data from in vivo experiments and clinical trials focusing on 
neurological disease models. 
 
 
2. MITOCHONDRIAL THERAPEUTIC STRATEGIES 
 
2.1. Preventing transmission by mitochondrial gene replacement 
 
Assisted conception strategies have the potential to prevent or at least reduce the risk of 
transmitting mitochondrial disease. Afflicted families can benefit from genetic counseling, but 
this is particularly challenging and associated with high level of uncertainty in the case of 
mtDNA mutations [21]. Pre-implantation genetic diagnosis (PGD) can assist selection of 
embryos without disease-linked nuclear DNA mutations. Mutations in mtDNA, however, are 
solely maternally inherited and may in principle be passed to all offspring, albeit in uncertain 
proportion. PGD to select embryos with very low mutant mtDNA levels reduces risk but does 
not eliminate the possibility that mitochondrial disease might manifest, or that asymptomatic 
girls will be carriers in their oocytes. Moreover, PGD is not helpful when homoplasmic 
mutations or high levels of heteroplasmic mtDNA mutations are already present in oocytes 
[22]. Development of other options for preventing transmission of mtDNA disease has thus 
been actively explored, primarily nuclear genome transplantation into the healthy mtDNA 
background of donor zygotes/oocytes via pronuclear or spindle transfer techniques [23, 24]. 
Pronuclear transfer into enucleated zygotes has been successfully applied in mice with 
pathogenic mtDNA mutations, yielding an F0 progeny free of respiration defects throughout 
their lives [25]. Proof of principle experiments with the same technique were conducted in 
abnormally fertilized human zygotes, achieving less than 2% carryover of mtDNA and thus 
supporting its potential to prevent mtDNA disease transmission in humans [26]. Another 
technique for mtDNA replacement, spindle-chromosome complex transfer, has been 
successfully applied to non-human primates generating healthy offspring without detectable 
spindle-donor mtDNA [27]. A recently-published 3-year follow up on those primates has 
shown that they continue to develop normally, with comparable growth and metabolic status 
to age-matched controls, and without significant changes in mtDNA carryover and 
heteroplasmy in blood and skin samples [28]. In the same publication, authors demonstrated 
the feasibility of replacing mtDNA in human oocytes via spindle transfer. Normally fertilized 
human oocytes developed comparably to controls into blastocysts, and the derived embryonic 
stem cell lines exhibited normal euploid karyotypes, with undetectable carryover mtDNA 
[28]. Still, the current frequency of premature activation/abnormal fertilization of human 
oocytes with the spindle transfer technique is far from ideal [28], and methodological changes 
have been recently proposed [29]. In spite of major and encouraging advances, further 
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efficacy and safety studies are required before either pronuclear or spindle transfer techniques 
can be introduced into clinical practice ([30]; see also the 2014 update of the UK’s Human 
Fertilisation and Embryology Authority report at: www.hfea.gov.uk/6372.html). As recently 
cautioned, however, pronuclear and spindle transfer may only benefit a small group of female 
mtDNA mutation carriers, whilst prenatal diagnostic testing can be used for all Mendelian 
mitochondrial disorders and for the majority of mtDNA mutations [31]. 
Polar body genome transfer has been recently proposed as an alternative technique for 
mtDNA replacement. This procedure, so far tested in mice, consists in transferring the genetic 
information of a polar body from a donor oocyte into a recipient oocyte with normal 
mitochondria [32]. Key advantages are that fewer mitochondria are carried over during 
transfer and, combined with spindle transfer, a single oocyte could offer two donor genome 
sources for a mtDNA replacement procedure, reducing the number of necessary donor 
oocytes [33]. Evidently, while all these techniques may prove useful for preventing 
mitochondrial disease transmission to newborn children, different approaches must be 
developed in order to treat symptomatic patients and to prevent disease in those already at risk 
[34]. 
 
 
2.2. Gene therapy to reduce or compensate for mutant mtDNA 
 
Pathogenic mtDNA mutations are most often heteroplasmic, meaning that they coexist with 
wild-type mtDNA. Some gene therapy strategies thus aim to shift the balance towards wild-
type mtDNA by reducing mutant mtDNA below the disease threshold. These include 
antigenomic approaches to halt replication of mutant mtDNA or mitochondrial-targeted 
nucleases to selectively degrade mutated mtDNA [35]. Other strategies compensate for 
mutant mtDNA via allotopic expression of the wild-type genes, or via xenotopic expression of 
cognate genes from other species [36]. Proof of principle in cellular models has been 
established for most of these strategies, but there is still very limited in vivo evidence for their 
safety and efficacy. Problems with delivery of the therapeutic agents to affected tissues 
remain main hindrances to drug development, together with the scarcity of good animal 
models for pre-clinical testing. Key strategies and their recent advances are summarized 
below. 
Antigenomic (or anti-replicative) therapies have been tested with sequence-specific nucleic 
acid derivatives, designed to bind mutant mtDNA and inhibit its replication, whilst allowing 
wild-type mtDNA propagation. Peptide nucleic acids (PNAs) showed promising in vitro 
results [37], but PNAs have so far failed to modulate heteroplasmy in intact cells, as a result 
of their inability to cross the IMM and access mtDNA [35]. Recently, RNA vectors based on 
5S rRNA or tRNA were reported capable of delivering anti-replicative oligoribonucleotides to 
mitochondria by exploring RNA import pathways. The same study reported a transient 15-
35% decrease in mutant mtDNA levels in Kearns Sayre syndrome cell models using such 
anti-replicative RNAs [38]. Attempts to increase these agents lifetime by chemical 
modification of the oligonucleotides have so far resulted in loss of efficacy [39, 40]. 
Restriction endonucleases fused to a mitochondria-targeting (mito-) sequence were shown 
to selectively reduce mtDNA containing the recognized restriction site [41]. Experiments with 
a heteroplasmic cell line showed that mito-SmaI selectively depleted pathogenic m8993T>G 
mtDNA allowing for repopulation with wild-type mtDNA [42]. In vivo experiments with 
NZB/BALB heteroplasmic mice showed that adenoviral vectors injected in brain and muscle 
efficiently delivered mito-ApaLI, which selectively degraded BALB mtDNA [43]. Systemic 
delivery of mito-ApaLI via cardiotropic (AAV6) or hepatotropic (Ad5) adeno-associated 
virus increased NZB mtDNA in target tissues [44], whereas AAV9-mediated delivery of 
Authors’	  version	  	  |	  Leitão-­‐Rocha	  et	  al	  (2015)	  Current	  Medicinal	  Chemistry	  22:	  2458-­‐2467	  |	  Pubmed–	  PMID:	  25666789	  
The	  published	  manuscript	  is	  available	  at	  EurekaSelect	  via	  http://www.eurekaselect.com/128349/article	  
	   5	  
mito-ApaLI to newborn mice reduced mtDNA heteroplasmy in all striated muscles, including 
the heart [45]. Endonuclease-mediated heteroplasmy shift is thus rapidly emerging as one of 
the most promising therapeutic approaches for mtDNA mutations. While the use of bacterial 
restriction nucleases requires a unique site in mutated mtDNA (but see the ‘differential 
multiple cleavage site model’; [46]), other nucleases are more versatile. Zinc-finger nucleases 
(ZFNs) can be engineered to bind a specific DNA sequence, and mito-ZFNs were shown to 
selectively degrade mutated mtDNA in heteroplasmic cells [47, 48]. The subsequently 
developed transcription activator-like effector nucleases (TALENs) are an interesting 
alternative to ZFNs [49]. Transient mito-TALENs expression in patient-derived cells reduced 
deletion or point-mutant mtDNA, fueling the expectation that a few mito-TALEN 
administrations may suffice to correct heteroplasmy and rescue oxidative phosphorylation 
defects [50]. Recently, novel obligatory heterodimeric mito-ZFNs have shown improved 
heteroplasmy shifting and rescue of mitochondrial respiration, meeting the efficiency of mito-
TALENs, with the advantage of being smaller constructs and thus more amenable to 
packaging in viral vectors [51]. Further development of these strategies, namely in vivo 
studies, are currently hindered by the size of the constructs, and challenged by the risk of 
severe mtDNA depletion, particularly in tissues containing high proportions of the targeted 
mutant mtDNA [34, 52]. 
Allotopic expression relies on nuclear-cytosolic synthesis of a recoded wild-type copy of 
the mutated mtDNA gene, plus its functional incorporation into mitochondria by means of a 
removable targeting signal. Feasibility was demonstrated in yeast, where cytoplasmically 
synthesized subunit 8 was successfully integrated into the mitochondrial ATPase complex  
[53]. Attempts in mammalian cells yielded contradictory results, and thus far lack 
unequivocal demonstration that the allotopically-expressed subunits assemble into the 
respective holoenzymes and are responsible for improved function [54]. Cytoplasmically 
synthesized ATPase 6 was reported to incorporate into mitochondria and rescue defective 
ATP synthesis in human cell lines with the m8993T>G mutation [55, 56]. Independent 
reformulation of these experiments, however, found neither evidence for ATPase 6 
incorporation into the ATP synthase holoenzyme, nor for improvement in mitochondrial 
function, suggesting that earlier studies might have been biased by random clonal variation in 
ATP synthesis within the aneuploid cell lines [57]. Similarly, successful allotopic expression 
of the ND4 subunit to rescue the m11778G>A LHON mutation in human cells [58] was 
contradicted by subsequent studies [59]. Experiments with mtDNA-encoded genes in 
mammalian cells showed that ATPase 8 could be allotopicaly expressed and localized to 
mitochondria, whereas the more hydrophobic ND4 and apocytochrome b formed aggregates 
and induced loss of mitochondrial membrane potential [59]. 
To overcome hidrophobicity issues, 3’UTR sequences were engineered into the mRNAs to 
target them near mitochondria and optimize co-translational translocation of the allotopically-
expressed gene. This optimized strategy was reported successful for the allotopic expression 
of ND1, ND4 and ATP6 to rescue mtDNA mutations affecting complex I and V in patients 
fibroblasts [60, 61]. Also, optimized allotopic expression of human ND4 was reported to 
prevent blindness in rats whose eyes were previously electroporated with human ND4 
harboring the m11778G>A LHON mutation [62]. Clinical trial recruitment of LHON patients 
carrying the m11778G>A mutation has started [63]. The trial identified as NCT01267422 
reports the random treatment of seven patients by single intravitreal injection of recombinant 
AAV2-ND4 (Clinicaltrials.gov, last processed on August 24, 2014). While some recent 
studies are supportive of the importance and strategies of these ND4 expression trials [64] 
[65], other studies caution that: (i) available data on allotopic expression is insufficient to 
initiate clinical trials in humans; (ii) reports of successful allotopic expression by phenotypic 
recovery in cells with mtDNA mutations may be explained by selection of revertants, without 
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mitochondrial internalization and/or holoenzyme incorporation of the expressed subunit; (iii) 
the conceptual validity of the mouse LHON model is questioned given the use of human 
mtDNA sequences, plus the possibility that ND4 hydrophobicity causes retinal toxicity by 
collapsing the mitochondrial import machinery [54]. 
Targeted tRNAs have been tested as a strategy to overcome mutations in mitochondrial 
tRNA (mt-tRNA) genes. Yeast tRNALys derivatives expressed in patient fibroblasts with the 
m8344A>G MERRF mutation were imported to mitochondria, correctly aminoacylated, and 
shown capable of rescuing mitochondrial translation and respiratory chain activity [66]. 
Interestingly, tRNA import appears more widespread than previously thought, with both rat 
and human mitochondria being capable of importing nucleus-encoded tRNAGln(CUG) and 
tRNAGln(UUG) in vivo, by a distinct mechanism from protein import [67]. A wide range of 
tRNAs and mRNAs may be targeted to mitochondria by appending the RNA component of 
human RNase P, which interacts with polynucleotine phosphorylase (PNPase) that facilitates 
delivery of the hybrid RNA into the mitochondrial matrix. Further appending a 3’-UTR 
localization sequence, however, was essential for efficient translocation of corrective mt-
tRNAs, shown capable of rescuing mitochondrial translation and respiratory defects in two 
human cell lines with mutant mt-tRNA genes [68]. 
Overexpression of aminoacyl tRNA synthetases is an alternative strategy to rescue cognate 
pathogenic mt-tRNA mutations and, more recently, non-cognate mutations [69]). 
Accordingly, modification of the mt-tRNA binding domain of human mitochondrial 
phenylalanyl-tRNA synthetase significantly improved the aminoacylation efficiency of mt-
tRNAPhe carrying the m611G>A MERRF mutation [70]. Overexpression of human 
mitochondrial valyl- or leucyl-tRNA synthetases increased, respectively, the steady-state 
levels of mutant mt-tRNAVal [71] or mt-tRNALeu(UUR) [72], consistent with increased stability 
of the charged mt-tRNA. Also, overexpression of mitochondrial leucyl-tRNA synthetase 
rescued mitochondrial translation and respiration in cells carrying the A3243G MELAS 
mutation in mt-tRNALeu(UUR) [73]. A related strategy consists in the allotopic expression of 
recombinant and importable tRNAs with altered aminoacylation identity. Yeast tRNAs with 
artificially changed identity, from cytoplasmic lysine to mitochondrial leucine, partially 
rescued mitochondrial translation, steady-state levels of mtDNA-encoded respiratory chain 
subunits, and cellular respiration in human cells with the A3243G MELAS mutation in mt-
tRNALeu [74]. More recently, human mitochondrial leucyl tRNA synthetase, particularly a 
carboxy terminal fragment, was reported to rescue respiratory deficiency induced by 
pathogenic mt-tRNA mutations [69, 75]. Mechanisms, particularly those involved in the 
suppression of non-cognate mutations, remain uncertain but unlikely to involve 
aminoacylation (domain absent from the carboxy terminal fragment), and are possibly related 
to stabilization of the mutant tRNAs. These findings raise the appealing possibility of 
developing a universal suppressor molecule for multiple mt-tRNA mutations [76]. 
Xenotopic expression of non-mammalian genes that can function as single respiratory 
chain subunits provides an encouraging alternative to allotopic expression. The rationale is 
that functional single subunits would obviate the need for integration into assembled multi-
protein complexes, which has been the crux of allotopically expressed mammalian subunits. 
The Ciona intestinalis single subunit alternative oxidase (AOX) or the Saccharomyces 
cerevisae single subunit NADH oxidase (Ndi1) have the potential to alleviate, respectively, 
deficiencies in cytochrome c oxidase (COX) or in complex I [36]. C. intestinalis AOX 
expression in human cells conferred cyanide resistance to mitochondrial substrate oxidation 
[77], and corrected decreased cell respiration, glucose and pyruvate dependency in COX15-
deficient fibroblasts derived from a patient with early fatal cardiomyopathy [78]. 
Xenotopically expressed AOX integrates the mammalian mitochondrial respiratory chain 
where it can transfer electrons from the reduced ubiquinone pool to oxygen, thus bypassing 
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downstream blockades. Unlike downstream complex III and IV, however, AOX is not a 
proton pump, and thus it is crucial to establish whether the advantages of a potential 
superoxide-limiting bypass outweigh the disadvantages of energy dissipation. AOX was 
safely expressed in mice (MitAOX) without obvious detrimental effects upon major 
physiological parameters, which suggests that AOX does not severely limit energy production 
when integrated in an otherwise normal respiratory chain. The increased survival of MitAOX 
mice exposed to lethal cyanide supports the possibility that AOX may counteract downstream 
respiratory chain impairment [79]. MitAOX mice are thus a promising tool for further 
evaluation of the therapeutic potential of AOX in mitochondrial disease. 
Expression of yeast Ndi1 restored NADH dehydrogenase activity in human cells lacking 
complex I activity due to ND4 gene mutation [80]. Ndi1 insensitivity to complex I inhibitors 
such as rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) promoted its 
testing in PD or LHON models induced with such compounds. Viral delivery of Ndi1 (rAAV-
NDI1) by unilateral injection to the substantia nigra protected mice from neuronal injury 
induced by either MPTP [81] or rotenone [82], providing in vivo evidence for functional 
complementation of complex I by Ndi1. Also, long term Ndi1 expression (>8months) was 
neuroprotective in a chronic (1-4 weeks) MPTP/probenecid mouse model [83]. Ndi1 
expression was also protective in rotenone-induced mouse models of mitochondrial optic 
neuropathy, preserving retinal function and ameliorating vision [84, 85]. Concerning in vivo 
genetic models, a study with drosophila PINK1/Parkin mutants showed that Ndi1 rescued 
PINK1-associated defects, but failed to rescue any of the Parkin mutant phenotypes. 
Significantly, PINK1 mutants exhibited decreased complex I activity, unlike Parkin mutants 
[86]. Further in vivo studies including mammalian genetic models of mitochondrial disease 
would help define the therapeutic potential of xenotopic expression. 
 
 
2.3. Lipophilic cations and mitochondria-targeted peptides 
 
Lipophilic cations and mitochondria-targeted peptides are important agents for in vivo drug 
delivery, allowing enhanced mitochondrial accumulation of otherwise poorly taken up 
molecules. These delivery strategies increase potency of the targeted compounds, decreasing 
the required dose as well as extramitochondrial metabolism, inactivation and side effects. 
These strategies have two important limitations: (i) they lack organ-specificity, leading to 
preferential accumulation in mitochondria-rich tissues; and (ii) the typically used chemicals 
tend to accumulate in the matrix and the matrix-facing surface of the IMM, by comparison 
with other important mitochondrial compartments [87]. 
Mitochondrial membrane potential (Δψm) drives accumulation of lipophylic cations such 
as triphenylphosphonium (TPP+) derivatives, whose concentration within mitochondria 
increases approximately 10-fold for every 60 mV of Δψm as described by the Nernst equation. 
The TPP+-modified ubiquinone, MitoQ, has been extensively investigated as a mitochondria 
targeted-antioxidant, and shown protective in multiple disease models [88]. Oral MitoQ 
improved survival and grip strength in the SOD1G93A mouse model of amyotrophic lateral 
sclerosis, in correlation with slower decline of mitochondrial respiration, reducing oxidative 
markers, astrogliolis and neuronal loss in the spinal cord [89]. MitoQ was also reported 
protective in rodent models of MPTP-induced PD [88]. A clinical trial in 128 patients treated 
for 12 month with MitoQ, however, failed to show any difference versus placebo in PD 
progression (NCT00329056 at Clinicaltrials.gov; [90]). Still, MitoQ was well tolerated and it 
remains to be ascertained whether early pre-symptomatic treatment, preceding overt 
dopaminergic degeneration, might prove beneficial in delaying the onset of PD. 
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Szeto-Schiller (SS) peptides are described to selectively target mitochondria and 
concentrate in the IMM, independently of Δψm, by yet uncertain mechanisms (but see [91]) 
even though the peptides contain a net positive charge at physiological pH [92]. Potential-
independent mitochondrial uptake would offer a significant advantage since dysfunctional 
mitochondria are likely to exhibit lower Δψm, thus excluding or limiting the uptake of Δψm–
dependent drugs such as lipophilic cations. SS peptides display antioxidant activity, with SS-
31 exerting protective effects in animal models of amyotrophic lateral sclerosis [93], PD [94], 
and in primary neurons derived from AD mice – an in vitro model where MitoQ was also 
found protective [95]. SS-31 was also reported to improve mitochondrial energetics and 
muscle performance in aged mice [96]. The ongoing and future clinical trials with a modified 
form of SS-31 [92] should help establish its therapeutic potential. 
Hemigramicidin-TEMPO conjugates are antioxidants targeted to mitochondria via peptides 
derived from the membrane-active antibiotic, gramicidin S, which carry the stable free radical 
4-amino-2,2,6,6-tetramethylpiperidine-N-oxyl (4-NH2-TEMPO) as a ROS scavenger [97]. 
XJB-5-131 is one of the most promising compounds in this class. The mitochondrial targeting 
moiety is an alkene peptide isostere modification of the Leu-D-Phe-Pro-Val-Orn gramicidin S 
segment, whose β-turn motif inserts into the mitochondrial membrane. This mitochondrial 
targeting strategy is Δψm-independent, avoiding exclusion of XJB-5-131 from depolarized 
mitochondria. XJB-5-131 was recently reported to enhance survival of primary neurons, 
reduce oxidative damage to mtDNA, improve mitochondrial function, and suppress motor 
decline in a HD mouse model [98]. 
Peptide-based-multi-walled carbon nanotubes are being developed as an alternative 
delivery system for therapeutic oligonucleotides against mtDNA mutations. Mitochondrial-
targeting of these nanotubes is promoted by functionalization with a 25 amino acid peptide 
derived from the N-terminal region of human COX subunit VIII [99]. While these carbon 
nanotubes can clearly be internalized by cultured phagocytes and colocalize with their 
mitochondria, the in vivo pharmacokinetics and the bioenergetic consequences of inserting 
possibly Δψm-collapsing tubes into mitochondrial membranes remain to be investigated. 
 
 
2.4. Modulation of mitochondrial dynamics 
 
2.4.1 Biogenesis and fission-fusion  
The induction of mitochondrial biogenesis is being actively explored as a strategy to 
overcome mitochondrial dysfunction. The peroxisome proliferator-activated receptor (PPAR) 
and its co-activator α (PGC-1α) play key regulatory roles in biogenesis activation, 
highlighting the PPAR/PGC-1 pathway as a druggable target. Transgenic expression of PGC-
1α or treatment with the PPAR agonist bezafibrate induced mitochondrial biogenesis in vivo, 
preventing mitochondrial myopathy in mice lacking an essential COX assembly factor in 
skeletal muscle [100]. Bezafibrate, however, failed to induce mitochondrial biogenesis in 
other COX deficient models [101], in contrast with PGC-1α overexpression or its indirect 
activation with the AMPK agonist AICAR [102]. Still, bezafibrate restored PGC-1α levels, 
induced mitochondrial biogenesis, and exerted neuroprotective effects in mouse models of 
either HD [103] or tau pathology [104]. Moreover, bezafibrate increased mitochondrial 
proteins and ATP generating capacity, being neuroprotective in a mouse model of 
mitochondrial encephalopathy [105]. Thus, whilst there is conflicting data on bezafibrate 
effects in skeletal muscle, data from neurological disease models suggest that it might be a 
promising compound for the treatment of mitochondrial-associated neurodegenerative 
disease. 
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PPAR-γ agonists, such as the thiazolidinediones rosiglitazone and pioglitazone, exhibited 
promising effects in pre-clinical models of neurodegeneration, but data from clinical trials are 
unsupportive of their use in AD patients [106], and their potential in the context of PD is still 
uncertain [107]. A tentative pre-clinical evaluation of the bioenergetic intermediate 
oxaloacetate, as potential treatment for AD and other neurodegenerative disorders, reported 
increased PGC-1α mRNA, activated mitochondrial biogenesis and hippocampal neurogenesis 
in C57Bl/6 mice [108]. 
Lysine deacetylases (KDACs), including the NAD+-dependent sirtuins, are reported to 
regulate mitochondrial biogenesis via modulation of PGC-1α activity and changes in gene 
expression, suggesting that KDAC modulatory drugs may provide a strategy to boost 
mitochondrial biogenesis [109, 110]. Increasing NAD+ availability through administration of 
the precursor nicotinamide riboside was reported to increase PGC-1α-dependent 
mitochondrial biogenesis, presenting beneficial effect in the Tg2576 AD mouse model [111]. 
Recently, nicotinamide riboside or MRLB-45696 (an inhibitor of the NAD+ consuming 
enzyme poly(ADP-ribose) polymerase – PARP1) were reported to increase mitochondrial 
biogenesis with promising results in mitochondrial myopathy models [112-114]. Still, further 
studies on dosage regimens and pharmacokinetic data are still required for a more detailed 
evaluation of the therapeutic potential of these NAD+ modulating strategies [115]. 
Exercise is a well-known activator of mitochondrial biogenesis by upregulating PGC-1α 
[116]. In addition to its effects on skeletal muscle, exercise training was shown to increase 
mitochondrial biogenesis in the brain [117], highlighting exercise as a complementary 
strategy for neuroprotection and management of mitochondrial-associated neurological 
disease [118]. 
Restoration of the mitochondrial fission-fusion equilibrium appeals as a therapeutic 
strategy for mitochondrial dysfunction, given the association between excessive 
mitochondrial fission and/or defective fusion in neurodegenerative disorders [119, 120]. The 
hydrazone M1 was recently identified as a small molecule mitochondrial fusion promoter, 
capable of inhibiting mitochondrial fragmentation and enhancing survival of MPP+-treated 
SH-SY5Y neuroblastoma cells. M1 dose-dependently increased mitochondrial fusion in Mfn1 
or Mfn2 single knockouts (KO), but not in Mfn1/2 double KO or OPA1 KO cells, suggesting 
it requires basal fusion activity, albeit the proposed mechanism of action is increased 
ATP5A/B expression levels [121]. Small molecule inhibitors of mitochondrial fission are also 
under investigation [122]. The selective Drp1 inhibitor mdivi-1 rescued abnormal 
mitochondrial dynamics induced by human mutant PINK1 in dopaminergic N27 neuronal 
cells [123], and was reported neuroprotective in rodent models with induced seizures [124] or 
ischemic injuries [125, 126]. A novel peptide inhibitor of Drp1, P110, selectively inhibited 
Drp1 activation and mitochondrial Drp1-Fis1 interaction only under stressed conditions in 
cultured neuronal cells. P110 reduced mitochondrial fragmentation in SH-SY5Y cells treated 
with MPP+ or mitochondrial uncoupler (CCCP), and reduced neurite loss in primary 
dopaminergic neurons challenged with MPP+ to model PD neurodegeneration [127]. P110 
was also reported to reduce mitochondrial fragmentation in HD cells, decreasing 
mitochondrial dysfunction, neuropathology and mortality in R6/2 HD mice [128]. 
 
 
2.4.2. Movement and mitophagy 
Stimulating mitochondrial movement is a possible strategy to overcome deficits in 
mitochondrial distribution, particularly in neurons where mitochondria must travel 
extensively to meet the variable energy and Ca2+-buffering needs of distant synapses. AD and 
HD brain samples present decreased tubulin acetylation and cellular models of these diseases 
exhibit impaired microtubule-dependent mitochondrial transport [129-131]. Inhibition of the 
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microtubule deacetylase HDAC6 with tubacin increased α-tubulin acetylation, promoting 
motor recruitment and enhancing bidirectional transport in HD cellular models [130]. Another 
HDAC6 inhibitor, tubastatin A, rescued mitochondrial transport in amyloid-β (Aβ) treated 
hippocampal neurons [131], as did HDAC6 deletion, which also improved memory function 
in AD mice without affecting Aβ plaque load [132]. HDAC6 inhibitors also corrected 
mitochondrial transport and reversed axonal loss in a mouse model of peripheral neuropathy 
[133]. The normally nuclear-located HDAC1 was suggested to play a critical role in axonal 
damage and abnormal mitochondrial transport, following neuroinflammatory stimuli 
(glutamate + TNFα) capable of evoking the Ca2+-dependent nuclear export of HDAC1 [134]. 
Further concerning Ca2+-dependent effects, pan-KDAC inhibitors were shown to improve 
neuronal Ca2+ recovery following glutamate receptor activation [135]. Moreover, HDAC1 
inhibition with MS275, but not HDAC6 inhibition with tubacin, prevented cytosolic HDAC1 
from disturbing mitochondrial transport following neuroinflammatory stimuli [134]. 
Available evidence therefore suggests that different KDACs may impair neuronal 
mitochondrial dynamics depending on the pathogenic insult. KDAC inhibition as a 
therapeutic strategy for rescuing mitochondrial transport must, nevertheless, be balanced 
against the possible interferences with other roles, namely that of HDAC6 in 
autophagy/mitophagy [109]. 
Mitophagy dysregulation, either defective or excessive, is associated with 
neurodegeneration [136]. Experiments in yeast suggest that mitophagy can be mechanistically 
separated from other forms of autophagy [137], prompting the search for selective mitophagy 
triggers in mammals. The PINK1/Parkin pathway appears to be a prominent player in 
mammalian mitophagy. Briefly, damaged mitochondria with collapsed Δψm fail to import and 
process PINK1, which accumulates outside mitochondria recruiting the ubiquitin-ligase 
Parkin. Ubiquitin-binding adaptors (e.g. p62, HDAC6) recognize ubiquitinated mitochondria 
and facilitate the interaction with the autophagosomal protein LC3, igniting a cascade that 
culminates in autophagosome-lysosome fusion and mitochondrial digestion [138]. The post-
mitotic nature of neurons and their extreme morphology pose a unique challenge for 
mitochondrial turnover, being unlikely that neurons follow the same mitophagy rules as most 
mammalian cells. Interestingly, it was recently reported that at least some neurons shed 
axonal mitochondria for transcellular degradation by adjacent astrocytes [139].  Also, major 
bioenergetic differences between neurons and cell lines raise doubts on the relevance of the 
PINK1/Parkin pathway in neuronal mitophagy [140] [141], but other studies are supportive of 
that pathway in neurons [142, 143], where mitochondrial deubiquitinase USP30 was recently 
reported to oppose parkin-mediated mitophagy [144]. Currently, the (patho)-physiological 
triggers for neuronal mitophagy and the mechanisms for handling damaged mitochondria in 
distant synapses remain insufficiently understood [138], thus posing an outstanding challenge 
for developing mitophagy-related therapeutic strategies. Still, a study with heteroplasmic 
cybrid cells reported a selection against a deleterious mtDNA mutation by means of Parkin 
overexpression, thus suggesting that this strategy of enhancing mitophagy may ameliorate 
certain mitochondrial diseases [145]. 
 
 
3. CONCLUDING REMARKS 
 
Currently available therapies for mitochondrial-associated neurological diseases are mostly 
palliative. Advances in understanding the molecular aetiology of mitochondrial dysfunction, 
together with breakthroughs in assisted conception, gene therapy and mitochondrial drug 
targeting strategies, fuel the expectation that effective preventive and disease-modifying 
therapeutics might be available in the near future. To achieve this goal, it is critical to develop 
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good in vivo models for pre-clinical studies, organize patient cohorts and registries, establish 
reliable biomarkers, and improve clinical trial design. As always, and particularly in the case 
of complex mitochondrial disorders, clinical research will benefit tremendously from the 
unravelling of molecular pathogenesis afforded by basic mitochondrial research. 
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